Nicotine therapeutic benefits: Difference between revisions
| Line 1,115: | Line 1,115: | ||
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36817162/ Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease.] === | === 2023: [https://pubmed.ncbi.nlm.nih.gov/36817162/ Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease.] === | ||
* Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson's disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo. | *Animal Study | ||
* | *Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson's disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo. | ||
* Ruan S, Xie J, Wang L, Guo L, Li Y, Fan W, Ji R, Gong Z, Xu Y, Mao J, Xie J. Front Pharmacol. 2023 Feb 2;14:1088957. doi: 10.3389/fphar.2023.1088957 | *In summary, Nic pretreatment ameliorates MPTP-induced dyskinesia and anxiety-like behavior in mice with PD. Nic was found to alleviate neuroapoptosis by improving nigrostriatal dopaminergic damage, reducing the accumulation of pathological p-α-syn, and inhibiting microglia activation and pro-inflammatory factor expression in the substantia nigra and striatal regions of mice brain under MPTP stimulation. These neuroprotective effects of Nic may be achieved by modulating the JNK and ERK signaling pathways in the nigrostriatal system, which was further confirmed by the pretreatment of 5-MOP to decline the brain metabolic activity of Nic. | ||
**Citation: Ruan S, Xie J, Wang L, Guo L, Li Y, Fan W, Ji R, Gong Z, Xu Y, Mao J, Xie J. Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease. Front Pharmacol. 2023 Feb 2;14:1088957. doi: 10.3389/fphar.2023.1088957. PMID: 36817162; PMCID: PMC9932206. | |||
***Acknowledgement: This study received funding from the National Science Foundation of China (Grant No. 32072344, 82101506, 32272455), the Scientific and Technological Project of Henan Province of China (Grant No. 182102310157) and the Scientific and Technological Project of China Tobacco Jiangsu Industrial Co., Ltd. (No. H202002). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Authors JX, RJ, and ZG were employed by China Tobacco Jiangsu Industrial Co., Ltd. | |||
===2023: [https://jamanetwork.com/journals/jamaneurology/article-abstract/2805037 Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune]=== | ===2023: [https://jamanetwork.com/journals/jamaneurology/article-abstract/2805037 Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune]=== | ||